🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am delighted to be a part of this comprehensive assessment of irAEs in almost 9000 patients treated on pembrolizumab clinical trials. ejcancer.com/article/S0959-…

Interesting and thorough analysis of extrachromosomal DNA which appears to correlate with worse outcome in GI cancers treated with anti-PD1 alone but better outcomes with chemo-immotherapy. nature.com/articles/s4146…

Impressive clinical responses to CD19 CAR-T in patients with autoimmune disease. 'Immunosuppressive therapy was completely stopped in all the patients.' nejm.org/doi/full/10.10…

Targeting antigens with TCR-T and vaccine simultaneously offers a potential strategy to enhance efficacy of both. aacrjournals.org/cancerimmunolr…

Intriguing mechansim underscoring the influence of cancer associated fibroblasts in treatment resistence. These cells are not just bystanders. science.org/doi/10.1126/sc…

We need to change the paradigm in LA-HNSCC. Adding anti-PD1/PDL1 concurrently or adjuvantly has not worked. I think the solution will come with better biomarkers, changing radiation dosing, and rationally applied therapy sequencing. thelancet.com/journals/lanon…

Hindsight is easy but PDL1 expression appears to strongly predict pCR. That should help pave the path forward. nature.com/articles/s4159…

Inflammatory tongue conditions appear to predispose to oral tongue cancer. Etiology remains unclear but beginning to understand why this disease is rising in incidence. ascopubs.org/doi/10.1200/JC…

This is what happens when one combines a biomarker defined patient population with effectively directed systemic therapy - median follow-up 26 months, no recurrences. nejm.org/doi/full/10.10…

Great study linking emotional distress to immunotherapy treatment outcomes. The effect size is similar to PDL1 status. Measures of psychological well-being should be part of every oncology assessment. nature.com/articles/s4159…

Remarkable work cataloguing the diversity and complexity of tumor associated macrophages. This will be a valuable tool in cancer immunotherapy. nature.com/articles/s4146…

This is remarkable work from the Surgery Branch - proof or principle that autologous T cells can be transduced with personalized neoantigen TCRs that produce clinical responses in patients with refractory colorectal cancer. nature.com/articles/s4159…

Mandated Medicaid coverage of the routine costs of clinical trial participation increases participation by 5% in underserved minorities. Why is this not universal across the country? ascopubs.org/doi/10.1200/JC…

Highlighting the temporal and spatial coordination of CD4/CD8/DC interactions. cell.com/cancer-cell/ab…

Elegant and effective. Really interesting approach to CAR-T engineering. nature.com/articles/s4159…

Great demonstration of anti-PD1 crossing blood-brain-barrier and reaching GBM tumors with signficant increase in CD8 and TME changes. Resistance is not a matter of drug not getting to the tumor. aacrjournals.org/cancerimmunolr…

High response rate of anti-PD1 in Kaposi's sarcoma. This should be the new standard of care. ascopubs.org/doi/10.1200/JC…

Encouraging results combining cabozantinib with anti-PD1 in HNSCC. Would be great to have a biomarker of efficacy to de-risk phase 3 given LEAP-10 data. aacrjournals.org/clincancerres/…

Post-surgical ctDNA MRD status is prognostic in colorectal cancer. I was especially intrigued that adjuvant chemotherapy seemed to have benefit almost entirely in MRD+ patients. nature.com/articles/s4159…

Infusion of autologous macrophages to treat liver cirrhosis. Notable that, after 1 year, there were no deaths in the experimental arm [n=27] and 3 in the control arm [n=24]. Could this replace liver transplant in the future? nature.com/articles/s4159…